Aligos Therapeutics Inc (ALGS) Stock Price, Quote & News

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-12575...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 466 6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States

Bwnuts Jan. 14 at 7:32 PM

$IMRX down 40% on good results. Board member buys shares today. This is how you do it. Maybe $ALGS can learn a thing or two.

1 · Reply

168_swingit Jan. 13 at 8:15 PM

$ALGS Boolish catalyst.....

0 · Reply

Teeemo16 Jan. 13 at 5:46 PM

$ALGS ALGS new CCO! Has a CV with stints at GERN, CRNX, ARWR, CHRS, Medivation… which seems like a pretty solid background for a guy choosing to go to a $54MIL mkt cap bio?? 🧐

0 · Reply

Bwnuts Jan. 13 at 4:34 PM

$ALGS $IMRX has a better chance of significant return than $ALGS IN 2026.

0 · Reply

Bwnuts Jan. 12 at 5:33 PM

$ALGS few hundred shares here and there and shorts drop it 6/% and falling.

0 · Reply

DavidLindsey521 Jan. 12 at 4:16 PM

$AMAT $ALGS Semiconductor leverage

0 · Reply

Bwnuts Jan. 12 at 3:20 PM

$ALGS here she goes.

0 · Reply

Bwnuts Jan. 12 at 3:09 PM

$ALGS closes in $7S today.

0 · Reply

Bwnuts Jan. 12 at 2:51 PM

$ALGS bid sitting at $8.81. This is the”maybe it will go up today” portion of the show. Next comes the shorts then come the stop losses.

0 · Reply

Bwnuts Jan. 9 at 9:24 PM

$ALGS I have the UBS analyst report. If you want ti, message me. Clearly the market liked it so much the stock dropped 13% today.

1 · Reply

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 8:00 AM EST - 4 weeks ago

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Nov 20, 2025, 7:43 PM EST - 7 weeks ago

Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 8:00 AM EST - 2 months ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Nov 6, 2025, 8:30 AM EST - 2 months ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 2 months ago

Aligos Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:30 AM EDT - 2 months ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Oct 16, 2025, 8:30 AM EDT - 3 months ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Oct 14, 2025, 8:30 AM EDT - 3 months ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Oct 7, 2025, 8:30 AM EDT - 3 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Sep 3, 2025, 4:05 PM EDT - 4 months ago

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Sep 2, 2025, 4:05 PM EDT - 4 months ago

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 5 months ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Aug 13, 2025, 8:30 AM EDT - 5 months ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 6 months ago

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

Jun 18, 2025, 8:00 AM EDT - 7 months ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

May 29, 2025, 8:00 AM EDT - 8 months ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 8 months ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

May 8, 2025, 8:00 AM EDT - 8 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

May 6, 2025, 8:00 AM EDT - 9 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 8:30 AM EDT - 9 months ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Apr 23, 2025, 4:05 PM EDT - 9 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Mar 26, 2025, 8:00 AM EDT - 10 months ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 10, 2025, 8:00 AM EDT - 11 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 11 months ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Feb 12, 2025, 7:00 AM EST - 1 year ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Nov 19, 2024, 1:30 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Present at Investor Conferences in October

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 18, 2024, 5:00 PM EDT - 1 year ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aug 15, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Reverse Stock Split

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Jul 22, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

May 22, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 21, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:05 PM EST - 2 years ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 20, 2024, 8:00 AM EST - 2 years ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Dec 7, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Nov 20, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Bwnuts Jan. 14 at 7:32 PM

$IMRX down 40% on good results. Board member buys shares today. This is how you do it. Maybe $ALGS can learn a thing or two.

1 · Reply

168_swingit Jan. 13 at 8:15 PM

$ALGS Boolish catalyst.....

0 · Reply

Teeemo16 Jan. 13 at 5:46 PM

$ALGS ALGS new CCO! Has a CV with stints at GERN, CRNX, ARWR, CHRS, Medivation… which seems like a pretty solid background for a guy choosing to go to a $54MIL mkt cap bio?? 🧐

0 · Reply

Bwnuts Jan. 13 at 4:34 PM

$ALGS $IMRX has a better chance of significant return than $ALGS IN 2026.

0 · Reply

Bwnuts Jan. 12 at 5:33 PM

$ALGS few hundred shares here and there and shorts drop it 6/% and falling.

0 · Reply

DavidLindsey521 Jan. 12 at 4:16 PM

$AMAT $ALGS Semiconductor leverage

0 · Reply

Bwnuts Jan. 12 at 3:20 PM

$ALGS here she goes.

0 · Reply

Bwnuts Jan. 12 at 3:09 PM

$ALGS closes in $7S today.

0 · Reply

Bwnuts Jan. 12 at 2:51 PM

$ALGS bid sitting at $8.81. This is the”maybe it will go up today” portion of the show. Next comes the shorts then come the stop losses.

0 · Reply

Bwnuts Jan. 9 at 9:24 PM

$ALGS I have the UBS analyst report. If you want ti, message me. Clearly the market liked it so much the stock dropped 13% today.

1 · Reply

Bwnuts Jan. 9 at 4:05 PM

$ALGS already a bearish engulfing daily candle 1.5 hours into the trading day. This thing always disappoints and the disappointments keep getting bigger. But don’t worry ..CEO just received equity in a new biotech startup and took the chairman role. He may also be recording a new album. I hear he plays a mean guitar. https://lawrenceblatt.com/bio

1 · Reply

Bwnuts Jan. 9 at 3:41 PM

$ALGS welcome new investors from the UBS Coverage initiation. It’s very normal around here to have your position blown up immediately and remain underwater for months and probably years. Welcome to the team.

0 · Reply

Bwnuts Jan. 9 at 2:50 PM

$ALGS https://finance.yahoo.com/news/onco3r-therapeutics-appoints-lawrence-blatt-080000490.html we never hear from him as is. Now another responsibility to distract him?

0 · Reply

Teeemo16 Jan. 8 at 9:49 PM

$ALGS Nice close above 50 day MA, and right on 20 day

0 · Reply

Bwnuts Jan. 8 at 6:46 PM

$ALGS can we break the 200 EMA and flip it to support vs resistance please?

0 · Reply

Bwnuts Jan. 8 at 3:47 PM

$ALGS and now back to your regularly scheduled programming of 200 EMA resistance.

0 · Reply

HedgeUrHedge Jan. 7 at 3:14 PM

$ALGS price target is now $700 a share for me now.

0 · Reply

HedgeUrHedge Jan. 7 at 3:13 PM

$ALGS highly suggest everyone cancel out the noise by shorts who say they are not short but are actually short lol. stick to facts

1 · Reply

Bwnuts Jan. 7 at 4:02 AM

$ALGS so who’s selling the Aligos story to Wall Street? I’ll wait.

0 · Reply

Bwnuts Jan. 6 at 3:01 PM

$ALGS with this pitiful volume, it’s a sitting duck just waiting for shorts to take it out.

0 · Reply

Bwnuts Jan. 5 at 9:30 PM

$ALGS $ALT worth $426M and this dumpster fire is worth $51M This needs new management yesterday.

2 · Reply

Bwnuts Jan. 5 at 9:26 PM

$ALGS these guys are getting lapped by the competition right and left. https://finance.yahoo.com/news/altimmune-receives-fda-breakthrough-therapy-123000425.html

1 · Reply

Market Cap	56.86M
Revenue (ttm)	3.95M
Net Income (ttm)	-131.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,321.77%
Debt to Equity Ratio	0.00

Volume	87,400
Avg Vol	76,028
Day's Range	N/A - N/A
Shares Out	6.15M
Stochastic %K	36%
Beta	2.64
Analysts	Strong Sell
Price Target	$76.25